Febuxostat, a novel drug for the treatment of hyperuricemia of gout

about

Gout--what are the treatment options?Febuxostat for the chronic management of hyperuricemia in patients with gout.Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase

P2860

Q37492596-42D21A5D-EA09-4236-8171-C99D0971E4E8 Q38760404-9FA51D8A-8754-4630-BEE2-227C8BCC8F53 Q57076754-A523865D-C1CC-4405-8EE4-AA8466FD1967

P2860

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

Item

http://www.wikidata.org/entity/Q57076791

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2008

@uk

name

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

@en

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

@nl

type

Item

label

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

@en

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

@nl

prefLabel

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

@en

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

@nl

P1476

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

@en

P2093

Naomi Schlesinger

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

Relation between adverse events associated with allopurinol and renal function in patients with gout

Serum urate levels and gout flares: analysis from managed care data.

Efficacy and safety of desensitization to allopurinol following cutaneous reactions.

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

P304

421-427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/17460816.3.5.421

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fernando Perez-Ruiz

Nicola Dalbeth

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

about

P2860

P2860

Febuxostat, a novel drug for the treatment of hyperuricemia of gout

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577